Physician profile
Kenneth E Stark
NPI 1558346262
$448,717.66
in general payments reported to CMS, 2019-2025
34 companies · $56K in 2025
The $56K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156K · 2020: $52K · 2021: $57K · 2022: $40K · 2023: $40K · 2024: $48K · 2025: $56K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Food and Beverage: $16K · Travel and Lodging: $7,177 · Consulting Fee: $4,600 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,191.00 |
| Food and Beverage | $16,173.75 |
| Travel and Lodging | $7,176.96 |
| Consulting Fee | $4,600.00 |
| Education | $151.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $146,853.21 | 2019-2025 | Evenity, Prolia, Enbrel |
| Ucb, INC. | $62,430.87 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Scientific Affairs, LLC | $62,033.63 | 2019-2023 | Simponi Aria, Stelara, Tremfya |
| Genzyme Corporation | $54,720.09 | 2019-2025 | |
| Janssen Biotech, INC. | $40,972.76 | 2019-2025 | Simponi Aria, Tremfya, Remicade |
| Genentech USA, INC. | $21,611.87 | 2019-2025 | Actemra |
| Pfizer INC. | $16,774.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $15,481.32 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $11,690.62 | 2019-2025 | Orencia |
| Regeneron Healthcare Solutions, INC. | $4,301.05 | 2019 | |
| Abbvie INC. | $3,798.21 | 2019-2025 | Rinvoq |
| Horizon Therapeutics Plc | $1,254.69 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $1,250.48 | 2020-2025 | Acthar |
| Lilly USA, LLC | $1,052.13 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Radius Health, INC. | $877.87 | 2019-2025 | Tymlos |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $815.16 | 2019-2025 | Benlysta, Nucala |
| Ani Pharmaceuticals, INC. | $640.90 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Sobi, INC | $477.32 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $458.05 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.96 | 2023-2025 | Ofev, Cyltezo |
| Janssen Pharmaceuticals, INC | $268.69 | 2019 | |
| Sanofi-Aventis U.S. LLC | $122.98 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $111.09 | 2019 | |
| Mallinckrodt Enterprises LLC | $89.66 | 2019 | |
| Aurinia Pharma U.S., INC. | $55.32 | 2022-2023 | Lupkynis |
| Organon LLC | $49.29 | 2021 | |
| Merck Sharp & Dohme LLC | $43.45 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $17.91 | 2021 | |
| Fresenius Kabi USA, LLC | $16.68 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2023 | Truxima |
| Sandoz INC. | $14.38 | 2025 | Hyrimoz |
| Pacira Therapeutics, INC. | $13.04 | 2019 | |
| Celgene Corporation | $11.98 | 2019 | |
| Medexus Pharma, INC. | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.